The p53 inhibitor pifithrin-α can stimulate fibrosis in a rat model of ischemic acute kidney injury

Pierre Dagher, Erik M. Mai, Takashi Hato, So Young Lee, Melissa Anderson, Stephanie C. Karozos, Henry E. Mang, Nicole L. Knipe, Zoya Plotkin, Timothy Sutton

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Inhibition of the tumor suppressor p53 diminishes tubular cell apoptosis and protects renal function in animal models of acute kidney injury (AKI). Therefore, targeting p53 has become an attractive therapeutic strategy in the approach to AKI. Although the acute protective effects of p53 inhibition in AKI have been examined, there is still relatively little known regarding the impact of acute p53 inhibition on the chronic sequelae of AKI. Consequently, we utilized the p53 inhibitor pifithrin- α to examine the long-term effects of p53 inhibition in a rodent model of ischemic AKI. Male Sprague-Dawley rats were subjected to bilateral renal artery clamping for 30 min followed by reperfusion for up to 8 wk. Pifithrin-α or vehicle control was administered at the time of surgery and then daily for 2 days [brief acute administration (BA)] or 7 days [prolonged acute administration (PA)]. Despite the acute protective effect of pifithrin- α in models of ischemic AKI, we found no protection in the microvascular rarefaction at 4 wk or development fibrosis at 8 wk with pifithrin- α administered on the BA schedule compared with vehicle control-treated animals. Furthermore, pifithrin- α administered on a PA schedule actually produced worse fibrosis compared with vehicle control animals after ischemic injury [21%/area (SD4.4) vs.16%/area (SD3.6)] as well as under sham conditions [2.6%/area (SD1.8) vs. 4.7%/area (SD1.3)]. The development of fibrosis with PA administration was independent of microvascular rarefaction. We identified enhanced extracellular matrix production, epithelial-to-mesenchymal transition, and amplified inflammatory responses as potential contributors to the augmented fibrosis observed with PA administration of pifithrin-α.

Original languageEnglish
JournalAmerican Journal of Physiology - Renal Physiology
Volume302
Issue number2
DOIs
StatePublished - Jan 2012

Fingerprint

Acute Kidney Injury
Fibrosis
Appointments and Schedules
Epithelial-Mesenchymal Transition
Renal Artery
Constriction
Reperfusion
Extracellular Matrix
Sprague Dawley Rats
pifithrin
Rodentia
Animal Models
Apoptosis
Kidney
Wounds and Injuries
Neoplasms

Keywords

  • Chronic
  • Fibronectin
  • Inflammation
  • Renal failure

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

The p53 inhibitor pifithrin-α can stimulate fibrosis in a rat model of ischemic acute kidney injury. / Dagher, Pierre; Mai, Erik M.; Hato, Takashi; Lee, So Young; Anderson, Melissa; Karozos, Stephanie C.; Mang, Henry E.; Knipe, Nicole L.; Plotkin, Zoya; Sutton, Timothy.

In: American Journal of Physiology - Renal Physiology, Vol. 302, No. 2, 01.2012.

Research output: Contribution to journalArticle

Dagher, Pierre ; Mai, Erik M. ; Hato, Takashi ; Lee, So Young ; Anderson, Melissa ; Karozos, Stephanie C. ; Mang, Henry E. ; Knipe, Nicole L. ; Plotkin, Zoya ; Sutton, Timothy. / The p53 inhibitor pifithrin-α can stimulate fibrosis in a rat model of ischemic acute kidney injury. In: American Journal of Physiology - Renal Physiology. 2012 ; Vol. 302, No. 2.
@article{0f7c0bf2642b42288637bc11df66faae,
title = "The p53 inhibitor pifithrin-α can stimulate fibrosis in a rat model of ischemic acute kidney injury",
abstract = "Inhibition of the tumor suppressor p53 diminishes tubular cell apoptosis and protects renal function in animal models of acute kidney injury (AKI). Therefore, targeting p53 has become an attractive therapeutic strategy in the approach to AKI. Although the acute protective effects of p53 inhibition in AKI have been examined, there is still relatively little known regarding the impact of acute p53 inhibition on the chronic sequelae of AKI. Consequently, we utilized the p53 inhibitor pifithrin- α to examine the long-term effects of p53 inhibition in a rodent model of ischemic AKI. Male Sprague-Dawley rats were subjected to bilateral renal artery clamping for 30 min followed by reperfusion for up to 8 wk. Pifithrin-α or vehicle control was administered at the time of surgery and then daily for 2 days [brief acute administration (BA)] or 7 days [prolonged acute administration (PA)]. Despite the acute protective effect of pifithrin- α in models of ischemic AKI, we found no protection in the microvascular rarefaction at 4 wk or development fibrosis at 8 wk with pifithrin- α administered on the BA schedule compared with vehicle control-treated animals. Furthermore, pifithrin- α administered on a PA schedule actually produced worse fibrosis compared with vehicle control animals after ischemic injury [21{\%}/area (SD4.4) vs.16{\%}/area (SD3.6)] as well as under sham conditions [2.6{\%}/area (SD1.8) vs. 4.7{\%}/area (SD1.3)]. The development of fibrosis with PA administration was independent of microvascular rarefaction. We identified enhanced extracellular matrix production, epithelial-to-mesenchymal transition, and amplified inflammatory responses as potential contributors to the augmented fibrosis observed with PA administration of pifithrin-α.",
keywords = "Chronic, Fibronectin, Inflammation, Renal failure",
author = "Pierre Dagher and Mai, {Erik M.} and Takashi Hato and Lee, {So Young} and Melissa Anderson and Karozos, {Stephanie C.} and Mang, {Henry E.} and Knipe, {Nicole L.} and Zoya Plotkin and Timothy Sutton",
year = "2012",
month = "1",
doi = "10.1152/ajprenal.00317.2011",
language = "English",
volume = "302",
journal = "American Journal of Physiology",
issn = "0193-1857",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - The p53 inhibitor pifithrin-α can stimulate fibrosis in a rat model of ischemic acute kidney injury

AU - Dagher, Pierre

AU - Mai, Erik M.

AU - Hato, Takashi

AU - Lee, So Young

AU - Anderson, Melissa

AU - Karozos, Stephanie C.

AU - Mang, Henry E.

AU - Knipe, Nicole L.

AU - Plotkin, Zoya

AU - Sutton, Timothy

PY - 2012/1

Y1 - 2012/1

N2 - Inhibition of the tumor suppressor p53 diminishes tubular cell apoptosis and protects renal function in animal models of acute kidney injury (AKI). Therefore, targeting p53 has become an attractive therapeutic strategy in the approach to AKI. Although the acute protective effects of p53 inhibition in AKI have been examined, there is still relatively little known regarding the impact of acute p53 inhibition on the chronic sequelae of AKI. Consequently, we utilized the p53 inhibitor pifithrin- α to examine the long-term effects of p53 inhibition in a rodent model of ischemic AKI. Male Sprague-Dawley rats were subjected to bilateral renal artery clamping for 30 min followed by reperfusion for up to 8 wk. Pifithrin-α or vehicle control was administered at the time of surgery and then daily for 2 days [brief acute administration (BA)] or 7 days [prolonged acute administration (PA)]. Despite the acute protective effect of pifithrin- α in models of ischemic AKI, we found no protection in the microvascular rarefaction at 4 wk or development fibrosis at 8 wk with pifithrin- α administered on the BA schedule compared with vehicle control-treated animals. Furthermore, pifithrin- α administered on a PA schedule actually produced worse fibrosis compared with vehicle control animals after ischemic injury [21%/area (SD4.4) vs.16%/area (SD3.6)] as well as under sham conditions [2.6%/area (SD1.8) vs. 4.7%/area (SD1.3)]. The development of fibrosis with PA administration was independent of microvascular rarefaction. We identified enhanced extracellular matrix production, epithelial-to-mesenchymal transition, and amplified inflammatory responses as potential contributors to the augmented fibrosis observed with PA administration of pifithrin-α.

AB - Inhibition of the tumor suppressor p53 diminishes tubular cell apoptosis and protects renal function in animal models of acute kidney injury (AKI). Therefore, targeting p53 has become an attractive therapeutic strategy in the approach to AKI. Although the acute protective effects of p53 inhibition in AKI have been examined, there is still relatively little known regarding the impact of acute p53 inhibition on the chronic sequelae of AKI. Consequently, we utilized the p53 inhibitor pifithrin- α to examine the long-term effects of p53 inhibition in a rodent model of ischemic AKI. Male Sprague-Dawley rats were subjected to bilateral renal artery clamping for 30 min followed by reperfusion for up to 8 wk. Pifithrin-α or vehicle control was administered at the time of surgery and then daily for 2 days [brief acute administration (BA)] or 7 days [prolonged acute administration (PA)]. Despite the acute protective effect of pifithrin- α in models of ischemic AKI, we found no protection in the microvascular rarefaction at 4 wk or development fibrosis at 8 wk with pifithrin- α administered on the BA schedule compared with vehicle control-treated animals. Furthermore, pifithrin- α administered on a PA schedule actually produced worse fibrosis compared with vehicle control animals after ischemic injury [21%/area (SD4.4) vs.16%/area (SD3.6)] as well as under sham conditions [2.6%/area (SD1.8) vs. 4.7%/area (SD1.3)]. The development of fibrosis with PA administration was independent of microvascular rarefaction. We identified enhanced extracellular matrix production, epithelial-to-mesenchymal transition, and amplified inflammatory responses as potential contributors to the augmented fibrosis observed with PA administration of pifithrin-α.

KW - Chronic

KW - Fibronectin

KW - Inflammation

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=84855297121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855297121&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00317.2011

DO - 10.1152/ajprenal.00317.2011

M3 - Article

C2 - 22049400

AN - SCOPUS:84855297121

VL - 302

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1857

IS - 2

ER -